Avidity Biosciences Inc
RNA36.365USD
+0.445+1.24%
Market hours （ET）Quotes delayed by 15 min
4.38BMarket Cap
LossP/E TTM
More Details of Avidity Biosciences Inc Company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Company Info
Ticker SymbolRNA
Company nameAvidity Biosciences Inc
IPO dateJun 12, 2020
CEOMs. Sarah Boyce
Number of employees391
Security typeOrdinary Share
Fiscal year-endJun 12
Address10578 Science Center Drive
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92121
Phone18584017900
Websitehttps://www.aviditybiosciences.com/
Ticker SymbolRNA
IPO dateJun 12, 2020
CEOMs. Sarah Boyce
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
1.57M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.08%
Investment Advisor
46.95%
Hedge Fund
6.31%
Venture Capital
5.98%
Corporation
4.21%
Research Firm
2.59%
Private Equity
1.94%
Individual Investor
1.01%
Sovereign Wealth Fund
0.60%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
495
141.64M
117.51%
-2.91M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
2023Q1
328
80.46M
115.95%
-5.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
15.29M
12.69%
-866.01K
-5.36%
Mar 31, 2025
Janus Henderson Investors
11.43M
9.48%
+4.37M
+62.01%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.21M
9.3%
+289.32K
+2.65%
Mar 31, 2025
Wellington Management Company, LLP
9.68M
8.03%
+1.58M
+19.47%
Mar 31, 2025
The Vanguard Group, Inc.
9.22M
7.65%
-188.71K
-2.01%
Mar 31, 2025
RTW Investments L.P.
8.75M
7.26%
+814.06K
+10.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.40M
6.96%
-22.20K
-0.26%
Mar 31, 2025
Avoro Capital Advisors LLC
7.63M
6.33%
+125.00K
+1.67%
Mar 31, 2025
RA Capital Management, LP
6.30M
5.23%
--
--
Mar 31, 2025
Bristol Myers Squibb
5.08M
4.21%
--
--
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Global X Genomics & Biotechnology ETF
3.64%
ALPS Medical Breakthroughs ETF
2.32%
Tema Neuroscience and Mental Health ETF
1.72%
SPDR S&P Biotech ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.38%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
View more
Global X Genomics & Biotechnology ETF
Proportion3.64%
ALPS Medical Breakthroughs ETF
Proportion2.32%
Tema Neuroscience and Mental Health ETF
Proportion1.72%
SPDR S&P Biotech ETF
Proportion0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.8%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.5%
ProShares Ultra Nasdaq Biotechnology
Proportion0.38%
Invesco Nasdaq Biotechnology ETF
Proportion0.38%
iShares Biotechnology ETF
Proportion0.32%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
